Company intelligence / Profile preview

Lixte Biotechnology Holdings, Inc.

Pasadena, California, United Stateslixte.com ↗

Ownership: Public · LIXT
Employees: ~4
Development stage: Phase 1

Overview

Lixte’s lead compound LB-100, a first-in-class PP2A inhibitor, has demonstrated synergy with both chemotherapy and immunotherapy in preclinical models and early clinical trials. It has shown to be well-tolerated at doses associated with anti-cancer activity. Multiple ongoing Phase I/II studies are evaluating its efficacy in combination regimens for solid tumors such as ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. Early results suggest enhanced treatment outcomes by promoting neoantigen production and T-cell proliferation while disrupting DNA repair in cancer cells

Therapeutic areas: OncologyHematology
Modalities: Small molecules (PP2A inhibitors)
Industry: Biotech

Drug pipeline

5 assets

LB-100

4 more assets in the full pipeline.

Request access →

Partnerships

The University of Texas MD Anderson Cancer CenterNetherlands Cancer InstituteSpanish Sarcoma GroupCollaborations with global pharmaceutical companies for clinical trials of LB‑100

Beyond the preview

Go deeper on Lixte Biotechnology Holdings, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lixte Biotechnology Holdings, Inc..

Explore the full profile